trending Market Intelligence /marketintelligence/en/news-insights/trending/PsQGjl2HPQ4M5EWpUcJlzQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

NanoString Technologies prices common stock offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

NanoString Technologies prices common stock offering

NanoString Technologies Inc. priced a public offering of common shares at $23 each.

The Seattle-based company is selling 2.5 million common shares under the offer, while private equity fund Clarus Lifesciences II LP, a NanoString stockholder, will sell 2 million shares. NanoString will not receive proceeds from the sale by Cambridge, Mass.-based Clarus.

NanoString also granted underwriters a 30-day option to buy up to an additional 675,000 common shares at the same price.

The company plans to use proceeds for working capital and general corporate purposes. The offer is expected to close on or about March 22.

J.P. Morgan, UBS Investment Bank and Cowen are acting as joint book-running managers for the offering, while Baird is acting as lead manager.

NanoString Technologies is a provider of life science tools for translational research and molecular diagnostic products.